Source:

Panaccione R, et al. Abstract LB11. Presented at: UEG Week; Oct. 3-5, 2021 (virtual meeting).

Disclosures: Panaccione reports consulting or speaking for AI4GI, AbbVie, Arena, Amgen, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring, Genentech, Gilead, Given Imaging, GlaxoSmithKline, Janssen, Lycera, Meda, Merck & Co., Merck Research, MerckSerono, Novo Nordisk, PDL Biopharma, Pfizer, Prometheus, Protagonist, Receptos, Robarts Clinical Trials, Salix, Soz, Sanofi Genzyme, Shire, Sigmoid, Sublimity, Takeda and Theravance.
October 11, 2021
1 min watch
Save

VIDEO: Rinvoq safe, effective as UC maintenance therapy

Source:

Panaccione R, et al. Abstract LB11. Presented at: UEG Week; Oct. 3-5, 2021 (virtual meeting).

Disclosures: Panaccione reports consulting or speaking for AI4GI, AbbVie, Arena, Amgen, Atlantic Healthcare, BioBalance, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Coronado Biosciences, Cosmo Technologies, Eagle, Eisai Medical Research, Elan, Eli Lilly, EnGene, Ferring, Genentech, Gilead, Given Imaging, GlaxoSmithKline, Janssen, Lycera, Meda, Merck & Co., Merck Research, MerckSerono, Novo Nordisk, PDL Biopharma, Pfizer, Prometheus, Protagonist, Receptos, Robarts Clinical Trials, Salix, Soz, Sanofi Genzyme, Shire, Sigmoid, Sublimity, Takeda and Theravance.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Remo Panaccione, MD, of the University of Calgary, reported Rinvoq safely and effectively maintained moderate-to-severe ulcerative colitis.

“Upadacitinib, which is on the market as Rinvoq [AbbVie] for rheumatoid arthritis, is expected to be approved in 2022 for the treatment of moderate to severe ulcerative colitis,” Panaccione said. “Seeing these impressive efficacy results and these striking differences over placebo bodes well for us as prescribers and for patients going forward with moderate to severe ulcerative colitis.”